| __timestamp | BioCryst Pharmaceuticals, Inc. | Zoetis Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 1643000000 |
| Thursday, January 1, 2015 | 13047000 | 1532000000 |
| Friday, January 1, 2016 | 11253000 | 1364000000 |
| Sunday, January 1, 2017 | 13933000 | 1334000000 |
| Monday, January 1, 2018 | 29514000 | 1484000000 |
| Tuesday, January 1, 2019 | 37121000 | 1638000000 |
| Wednesday, January 1, 2020 | 67929000 | 1726000000 |
| Friday, January 1, 2021 | 118818000 | 2001000000 |
| Saturday, January 1, 2022 | 159371000 | 2009000000 |
| Sunday, January 1, 2023 | 213894000 | 2151000000 |
| Monday, January 1, 2024 | 2318000000 |
Unveiling the hidden dimensions of data
In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. This analysis compares Zoetis Inc. and BioCryst Pharmaceuticals, Inc. from 2014 to 2023. Zoetis, a leader in animal health, consistently outpaces BioCryst, a niche player in rare diseases, in SG&A spending. In 2023, Zoetis's SG&A expenses were approximately 10 times higher than BioCryst's, reflecting its larger scale and market reach. Over the decade, Zoetis's expenses grew by about 31%, while BioCryst saw a staggering increase of over 270%, indicating aggressive expansion efforts. This trend highlights the contrasting strategies: Zoetis's steady growth versus BioCryst's rapid scaling. Understanding these dynamics offers insights into how each company navigates the competitive landscape, balancing growth with operational efficiency.
AbbVie Inc. vs Zoetis Inc.: SG&A Expense Trends
Gilead Sciences, Inc. and Zoetis Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Zoetis Inc. vs Teva Pharmaceutical Industries Limited Trends and Insights
SG&A Efficiency Analysis: Comparing Zoetis Inc. and Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: Zoetis Inc. vs Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Zoetis Inc. and Mesoblast Limited
Comparing SG&A Expenses: Zoetis Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Viridian Therapeutics, Inc.
Comparing SG&A Expenses: United Therapeutics Corporation vs BioCryst Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Incyte Corporation vs BioCryst Pharmaceuticals, Inc.
Ligand Pharmaceuticals Incorporated or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Amphastar Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.